Amphastar Pharmaceuticals (AMPH) to Release Quarterly Earnings on Wednesday

Amphastar Pharmaceuticals (NASDAQ:AMPHGet Free Report) is set to post its quarterly earnings results on Wednesday, February 28th.

Amphastar Pharmaceuticals Price Performance

AMPH opened at $55.09 on Tuesday. The stock’s 50 day simple moving average is $56.47 and its 200 day simple moving average is $52.97. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.11 and a quick ratio of 1.68. Amphastar Pharmaceuticals has a 1 year low of $31.86 and a 1 year high of $67.66. The firm has a market cap of $2.64 billion, a price-to-earnings ratio of 21.52, a PEG ratio of 0.67 and a beta of 0.90.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Bank of America assumed coverage on Amphastar Pharmaceuticals in a research report on Friday, November 17th. They set a “neutral” rating and a $63.00 price target on the stock. StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, February 5th.

View Our Latest Stock Analysis on AMPH

Insider Activity at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 4,316 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $58.58, for a total transaction of $252,831.28. Following the sale, the executive vice president now directly owns 112,420 shares in the company, valued at $6,585,563.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 500 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $61.37, for a total transaction of $30,685.00. Following the completion of the transaction, the director now owns 80,833 shares in the company, valued at $4,960,721.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Rong Zhou sold 4,316 shares of Amphastar Pharmaceuticals stock in a transaction on Friday, December 1st. The shares were sold at an average price of $58.58, for a total value of $252,831.28. Following the transaction, the executive vice president now owns 112,420 shares of the company’s stock, valued at approximately $6,585,563.60. The disclosure for this sale can be found here. Insiders have sold 274,360 shares of company stock worth $15,596,383 over the last ninety days. 28.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can lifted its holdings in shares of Amphastar Pharmaceuticals by 2.9% during the first quarter. Bank of Montreal Can now owns 13,029 shares of the company’s stock valued at $477,000 after purchasing an additional 371 shares in the last quarter. Envestnet Asset Management Inc. increased its position in Amphastar Pharmaceuticals by 4.2% during the second quarter. Envestnet Asset Management Inc. now owns 9,457 shares of the company’s stock valued at $543,000 after acquiring an additional 380 shares during the last quarter. Tudor Investment Corp Et Al increased its position in Amphastar Pharmaceuticals by 1.6% during the third quarter. Tudor Investment Corp Et Al now owns 24,503 shares of the company’s stock valued at $1,127,000 after acquiring an additional 396 shares during the last quarter. Royal Bank of Canada increased its position in Amphastar Pharmaceuticals by 19.1% during the third quarter. Royal Bank of Canada now owns 4,011 shares of the company’s stock valued at $112,000 after acquiring an additional 644 shares during the last quarter. Finally, Victory Capital Management Inc. increased its position in Amphastar Pharmaceuticals by 1.8% during the fourth quarter. Victory Capital Management Inc. now owns 37,092 shares of the company’s stock valued at $1,039,000 after acquiring an additional 665 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

(Get Free Report)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).

Further Reading

Earnings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.